Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 19
2003 22
2004 25
2005 30
2006 22
2007 17
2008 20
2009 17
2010 19
2011 13
2012 21
2013 10
2014 10
2015 5
2016 1
2017 1
2018 2
2019 1
2020 2
2021 2
2022 1
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Results by year

Filters applied: . Clear all
Page 1
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Judson I, et al. Among authors: verweij j. Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470-2045(14)70063-4. Epub 2014 Mar 5. Lancet Oncol. 2014. PMID: 24618336 Clinical Trial.
The epothilone dilemma.
de Jonge M, Verweij J. de Jonge M, et al. Among authors: verweij j. J Clin Oncol. 2005 Dec 20;23(36):9048-50. doi: 10.1200/JCO.2005.03.8844. Epub 2005 Nov 21. J Clin Oncol. 2005. PMID: 16301592 No abstract available.
Gynaecological sarcomas.
Sleijfer S, Seynaeve C, Verweij J. Sleijfer S, et al. Among authors: verweij j. Curr Opin Oncol. 2007 Sep;19(5):492-6. doi: 10.1097/CCO.0b013e3282748eaa. Curr Opin Oncol. 2007. PMID: 17762577 Review.
Phase I studies of drug combinations.
Verweij J, Disis ML, Cannistra SA. Verweij J, et al. J Clin Oncol. 2010 Oct 20;28(30):4545-6. doi: 10.1200/JCO.2010.30.6282. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855831 No abstract available.
Precision oncology: an overview.
Garraway LA, Verweij J, Ballman KV. Garraway LA, et al. Among authors: verweij j. J Clin Oncol. 2013 May 20;31(15):1803-5. doi: 10.1200/JCO.2013.49.4799. Epub 2013 Apr 15. J Clin Oncol. 2013. PMID: 23589545 No abstract available.
Medicinal cannabis in oncology.
Engels FK, de Jong FA, Mathijssen RH, Erkens JA, Herings RM, Verweij J. Engels FK, et al. Among authors: verweij j. Eur J Cancer. 2007 Dec;43(18):2638-44. doi: 10.1016/j.ejca.2007.09.010. Epub 2007 Oct 31. Eur J Cancer. 2007. PMID: 17976975 Review.
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Demetri GD, et al. Among authors: verweij j. Lancet. 2006 Oct 14;368(9544):1329-38. doi: 10.1016/S0140-6736(06)69446-4. Lancet. 2006. PMID: 17046465 Clinical Trial.
Renal toxicities of chemotherapy.
de Jonge MJ, Verweij J. de Jonge MJ, et al. Among authors: verweij j. Semin Oncol. 2006 Feb;33(1):68-73. doi: 10.1053/j.seminoncol.2005.11.011. Semin Oncol. 2006. PMID: 16473645 Review.
Verweij J. Verweij J. Cancer Chemother Biol Response Modif. 2002;20:559-73. Cancer Chemother Biol Response Modif. 2002. PMID: 12703224 Review. No abstract available.
240 results